Court rules hospital can withdraw life support for sick baby

KFOR, 27 June 2017
Author: Nadia Judith Enchassi
“The European Court of Human Rights ruled Tuesday a hospital can discontinue life support to a baby suffering from a rare genetic disease. Born in August, Charlie Gard has a rare genetic disorder caused by a genetic mutation that leads to weakened muscles and organ dysfunction, among other symptoms, with a poor prognosis for most patients. Charlie is on life support and has been in the intensive care unit at the Great Ormond Street Hospital for Children in London since October. His doctors wish to take him off life support, but his parents disagreed.”
Find article here.

A Clinic Mix-Up Leaves Pregnant Woman In Dark About Zika Risk

KHN, 21 June 2017
Author: Jonel Aleccia
“Hospital officials in Washington state have apologized after failing for months to inform a pregnant woman she was likely infected with the Zika virus that can cause devastating birth defects. Andrea Pardo was tested for the virus in October, after becoming pregnant while living in Mexico. The results were ready by December, but she wasn’t notified until April just before she delivered her daughter. The delay, blamed on a mistake at the University of Washington clinic where Pardo received care, deprived her of the chance to make an informed choice about her pregnancy.”
Find article here.

Pfizer, Roche and Aspen face South African probe into cancer drug prices

Reuters, 14 June 2017
Authors: Paul Arnold, Tiisetso Motsoeneng
“South Africa’s competition watchdog has launched an investigation into three drug companies accused of over-charging for cancer medicines, the agency’s chief said on Tuesday. The Commission, which investigates cases before bringing them to the Competition Tribunal for adjudication, said it suspected the lung cancer treatment xalkori crizotinib sold by Pfizer had been excessively priced as has the breast cancer drugs Herceptin and Herclon sold by Roche. It Commission also would look into whether Aspen might have over-charged for Leukeran, Alkeran and Myleran cancer treatments in South Africa.”
Find article here.

Merck & Co. Halts Enrollment in Two Keytruda Trials, Citing Deaths

GEN, 13 June 2017
Source: Genetic Engineering & Biotechnology News
“Merck & Co. said it has stopped enrollment in two Phase III trials assessing its cancer immunotherapy Keytruda® (pembrolizumab) in combination with other therapies to treat multiple myeloma, following reports of patient deaths. Patients currently enrolled in the two studies will continue to receive treatment, Merck said, adding that its other clinical studies of Keytruda will continue unchanged.”
Find article here.

Women urged to speak up on painful transvaginal mesh implant side effects

ABC, 31 May 2017
Author: Sophie Scott and Alison Branley
“The number of women who have experienced catastrophic side effects from a medical device used to treat prolapse after childbirth is likely to be higher than expected, experts fear. A Victorian health consumer group has conducted the first comprehensive survey of Australian women who have been treated with transvaginal mesh implants and they have received more than 1,850 responses in just six weeks, with more than 750 women saying they have had adverse effects. Reported problems from the device include incontinence, severe chronic pain, problems walking, painful intercourse and even marital breakdown.The Australian Commission on Safety and Quality in Health Care is now reviewing the use of the implants.”
Find article here.

Valium recall: Worker sacked over Roche diazepam tampering

ABC News, 31 May 2017
Source: ABC News
“A worker has been sacked after the TGA issued a nation-wide recall of Roche Products’ diazepam, because the relaxant had been swapped out for different drugs at a Sydney distribution centre. Roche said the incident occurred at a distribution centre, and this afternoon, Symbion Contract Logistics released a statement saying they had sacked a worker at its Sydney-based distribution facility.”
Find article here.

Sigma shares plunge on legal wrangle

News, 24 May 2017
Author: Melissa Jenkins
“Sigma Healthcare is planning legal action against the My Chemist/ Chemist Warehouse Group over an alleged breach of a supply agreement, sparking a dive in its share price. Sigma said its proposed action relates to the My Chemist/ Chemist Warehouse Group’s intention to obtain certain products from another wholesaler, which Sigma maintains it is not entitled to do under their existing agreement.”
Find article here.

French drugmaker Servier to face trial over weight-loss Mediator

Reuters, 24 May 2017
Authors: Simond Carraud, Matthias Blamont, Emmanuel Jarry and Leigh Thomas
“The Paris prosecutor’s office said on Wednesday that drugmaker Servier as well as the French drug regulator should face trial over weight-loss pill Mediator, believed to have caused at least 500 deaths in one of France’s worst health scandals. Once licensed as a diabetes treatment, the drug was widely prescribed as an appetite suppressant to help people lose weight. The prosecutor’s indictment covers charges of misleading claims as well as manslaughter and targets 14 people as well as 11 institutions including Servier and the French drug regulator ANSM.”
Find article here.

Deadly brain infection in German MS patient prompts Roche investigation

Reuters, 24 May 2017
Authors: John Miller, Bill Berkrot, Greg Mahlich and Lisa Shumaker
“A person in Germany treated with Roche Holding AG’s new multiple sclerosis drug Ocrevus has been diagnosed with an often-deadly brain infection after switching from another medication earlier this year. Roche said it was investigating a case of Progressive Multifocal Leukoencephalopathy (PML) in a patient previously being treated for three years with Biogen Inc’s Tysabri and who had received a single dose of Ocrevus in February. Ocrevus was approved in the United States in March.”
Find article here.